

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:126648-2019:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products
2019/S 055-126648**

Contract award notice

Results of the procurement procedure

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The NHS Commissioning Board (operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
United Kingdom
E-mail: gemma.tomlinson1@nhs.net
NUTS code: UK

Internet address(es):

Main address: <https://nhsengland.bravosolution.co.uk>

I.2) Information about joint procurement

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

National Framework Agreement for the Supply of Generic Pharmaceuticals — Tenofovir Disoproxil/Emtricitabine and Tenofovir Disoproxil/Emtricitabine/Efavirenz
Reference number: CM/PHG/17/5545

II.1.2) Main CPV code

33600000

II.1.3) Type of contract

Supplies

II.1.4) Short description:

Invitation to offer for National Framework Agreement for the Supply of Generic Pharmaceuticals — Tenofovir Disoproxil/Emtricitabine and Tenofovir Disoproxil/Emtricitabine/Efavirenz.
Offer reference number: CM/PHG/17/5545

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months.

Potential periods of call-offs under the Framework Agreement:

- North West London: 21.5.2019 to 31.10.2020 (18 months),
- North Central and East London: 21.5.2019 to 31.10.2020 (18 months),
- South East and West London: 21.5.2019 to 31.10.2020 (18 months),
- North of England: 21.5.2019 to 31.10.2020 (18 months),
- Midlands and East: 21.5.2019 to 31.10.2020 (18 months),
- South of England: 21.5.2019 to 31.10.2020 (18 months).

II.1.6) **Information about lots**

This contract is divided into lots: yes

II.1.7) **Total value of the procurement (excluding VAT)**

Value excluding VAT: 18 000 000.00 GBP

II.2) **Description**

II.2.1) **Title:**

Lot 1: London
Lot No: 1a & 1b

II.2.2) **Additional CPV code(s)**

33600000
33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points. The Framework Agreement is intended for use by the DHSC, Public Health England and the NHS in England.

II.2.4) **Description of the procurement:**

Lot 1a: London: Tenofovir Disoproxil/Emtricitabine.

Offer reference number: CM/PHG/17/5545/01

Lot 1b: London: Tenofovir Disoproxil/Emtricitabine/Efavirenz.

Offer reference number: CM/PHG/17/5545/02

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months.

Potential periods of call-offs under the Framework Agreement:

- North West London: 21.5.2019 to 31.10.2020 (18 months),
- North Central and East London: 21.5.2019 to 31.10.2020 (18 months),
- South East and West London: 21.5.2019 to 31.10.2020 (18 months).

II.2.5) **Award criteria**

Quality criterion - Name: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: See above

Price - Weighting: See above

II.2.11) **Information about options**

Options: yes

Description of options:

This Framework Agreement has the options to extend up to a period of 18 months.

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Lot 2: Rest of England

Lot No: 2a & 2b

II.2.2) **Additional CPV code(s)**

33600000

33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points. The Framework Agreement is intended for use by the DHSC, Public Health England and the NHS in England.

II.2.4) **Description of the procurement:**

Lot 2a: Rest of England: Tenofovir Disoproxil/Emtricitabine

Offer reference number: CM/PHG/17/5545/03

Lot 2b: Rest of England: Tenofovir Disoproxil/Emtricitabine/Efavirenz.

Offer reference number: CM/PHG/17/5545/04

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months.

Potential periods of call-offs under the Framework Agreement:

— North of England: 21.5.2019 to 31.10.2020 (18 months),

— Midlands and East: 21.5.2019 to 31.10.2020 (18 months),

— South of England: 21.5.2019 to 31.10.2020 (18 months).

II.2.5) **Award criteria**

Quality criterion - Name: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: See above

Price - Weighting: See above

II.2.11) **Information about options**

Options: yes

Description of options:

This Framework Agreement has the options to extend up to a period of 18 months.

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**

Open procedure

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

IV.1.6) **Information about electronic auction**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

Notice number in the OJ S: [2018/S 227-518883](#)

IV.2.8) **Information about termination of dynamic purchasing system**

IV.2.9) **Information about termination of call for competition in the form of a prior information notice**

Section V: Award of contract

Contract No: CM/PHG/17/5545/01 & CM/PHG/17/5545/02

Lot No: 1a & 1b

Title:

London: Tenofovir Disoproxil/Emtricitabine and London: Tenofovir Disoproxil/Emtricitabine/Efavirenz

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

12/02/2019

V.2.2) **Information about tenders**

Number of tenders received: 7

Number of tenders received from SMEs: 3

Number of tenders received by electronic means: 7

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Please see Section VI.3) for list of awarded suppliers

Please see Section VI.3) for list of awarded suppliers

United Kingdom

NUTS code: UK

The contractor is an SME: yes

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 9 000 000.00 GBP

V.2.5) **Information about subcontracting**

Section V: Award of contract

Contract No: CM/PHG/17/5545/03 & CM/PHG/17/5545/04

Lot No: 2a & 2b

Title:

Rest of England: Tenofovir Disoproxil/Emtricitabine and Rest of England: Tenofovir Disoproxil/Emtricitabine/Efavirenz

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

12/02/2019

V.2.2) **Information about tenders**

Number of tenders received: 7

Number of tenders received from SMEs: 3

Number of tenders received by electronic means: 7

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Please see Section VI.3) for list of awarded suppliers

Please see Section VI.3) for list of awarded suppliers

United Kingdom

NUTS code: UK

The contractor is an SME: yes

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 9 000 000.00 GBP

V.2.5) **Information about subcontracting**

Section VI: Complementary information

VI.3) **Additional information:**

Please see list of awarded suppliers (Including SME status) at the following website: <https://www.gov.uk/contracts-finder>

VI.4) **Procedures for review**

VI.4.1) **Review body**

The Royal Courts of Justice

London or any other district registry of the High Court

United Kingdom

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**

13/03/2019